Amarin buys Ester, gains mRNA tech

Amarin Corporation has bought Israel-based Ester Neurosciences, and R&D operation focused on messenger RNA (mRNA) silencing technology which targets the cholinergic pathway. Ester is also has a Phase II compound for myasthenia gravis and a preclinical program in neurodegenerative and inflammatory diseases. The deal could be worth up to $32 million; Amarin is initially paying Ester $15 million.

"This acquisition allows Amarin to gain access to a unique mRNA platform technology based on breakthrough discoveries in cholinergic neuromodulation. The validation of the platform via the promising clinical data from a Phase II study in myasthenia gravis adds substantial value to Amarin's neuroscience portfolio," noted Amarin CEO Rick Stewart.

- see this release for more on the deal

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.